Uveal Melanoma clinical trials
27 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Adjuvant Tebentafusp in High Risk Ocular Melanoma
- Neoadjuvant Tebentafusp for Uveal Melanoma
- Tebentafusp-tebn With LDT in Metastatic UM
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
- Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Adjuvant Quisinostat in High-Risk Uveal Melanoma
- Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- A Study of CRD3874-SI in People With Solid Tumors
- DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
- Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
- Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Uveal Melanoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.